KRAS and colorectal carcinoma: Similarly, Fuentes et al., found that n-3 PUFA specifically suppress oncogenic KRAS-driven CRC by 1) incorporating into plasma membrane PL, 2) modifying KRAS nanoscale proteolipid composition, 3) disrupting oncogenic KRAS driven signaling, and finally 4) suppressing KRAS-associated phenotypes in vitro and in vivo (Fuentes et al., 2018).